Skip to content

Corporate legal expenditures in India surpass $8 billion, encompassing compliance costs, legal disputes, and business deal negotiations

Businesses in India saw a substantial uptick in legal costs between the years of 2024 and 2025, notably with the emergence of a novel corporation...

Corporate Legal Costs in India Reach $8 Billion due to Compliance, Disputes, and Deal-Related...
Corporate Legal Costs in India Reach $8 Billion due to Compliance, Disputes, and Deal-Related Activities

In the dynamic world of Indian business, there are several noteworthy updates to share. Let's delve into the latest happenings.

Bharat Biotech, the manufacturer of Covaxin, is experiencing a resurgence after a post-Covid slump. The company's growth trajectory is once again on an upward trend, as reported in our articles, "Searchlight: Covaxin maker Bharat Biotech back on growth track after post-Covid slump" and "The Searchlight: Bharat Biotech".

Meanwhile, another significant development comes from the tech sector. A company named Fundamentum, backed by Nandan Nilekani, has adopted a dual strategy for growth-stage and AI-deeptech investments. This strategic move is detailed in our article, "Nilekani-backed Fundamentum charts dual strategy for growth-stage, AI-deeptech bets".

However, the competitive landscape presents challenges for some companies. For instance, MDIndia, a specific company, has reported a profit recovery in FY25, as per a separate article, but competitive pressures remain a potential concern, as mentioned in the same article.

In the realm of legal expenses, it's worth noting that a new company has joined the top 10 spenders among the approximately 1,700 companies analysed, which provided the necessary data. The total legal expenses for these companies increased by a double-digit percentage during the year through March 2025. However, companies such as Vistaar, Fundamentum, or Bharat Biotech were not included in this analysis.

Vistaar, a company backed by Warburg, is currently facing challenges due to rising Non-Performing Assets (NPAs) and credit costs, as revealed in our article, "Bottomline: Warburg-backed Vistaar hit by rising NPAs, credit costs".

For those interested in exclusive, curated articles, our PRO subscription offers privileged access. Don't miss our recommended article, "Searchlight: MDIndia posts profit recovery in FY25, but competitive pressures loom".

Lastly, we remind our PRO members that log-in is available on our website for continued access to our exclusive content. Stay tuned for more updates as we continue to bring you the latest news from the Indian business scene.

Read also:

Latest